Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/de-gruyter/successful-immune-tolerance-in-two-children-with-severe-haemophilia-a-SfIECGN8HI
References (17)
-
M. Manco‐Johnson, Thomas Abshire, A. Shapiro, B. Riske, Michele Hacker, R. Kilcoyne, J. Ingram, Michael Manco-Johnson, S. Funk, L. Jacobson, Leonard Valentino, W. Hoots, George Buchanan, D. DiMichele, M. Recht, Deborah Brown, C. Leissinger, Shirley Bleak, Alan Cohen, P. Mathew, A. Matsunaga, D. Medeiros, D. Nugent, Gregory Thomas, Alexis Thompson, K. McRedmond, J. Soucie, H. Austin, Bruce Evatt (2007)
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.The New England journal of medicine, 357 6
-
W. Kreuz, C. Ettingshausen, A. Zyschka, J. Oldenburg, I. Saguer, S. Ehrenforth, T. Klingebiel (2002)
Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.Seminars in thrombosis and hemostasis, 28 3
-
E. Berntorp (2011)
Importance of rapid bleeding control in haemophilia complicated by inhibitorsHaemophilia, 17
-
B. Konkle, L. Ebbesen, E. Erhardtsen, R. Bianco, T. Lissitchkov, L. Rusen, M. Serban (2007)
Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitorsJournal of Thrombosis and Haemostasis, 5
-
D. DiMichele, B. Kroner, S. Adair, J. Addiego, V. Anderson, J. Barbosa, P. Blatt, P. Bockenstedt, V. Castle, P. Chenaille, J. Cohen, E. Czapek, J. Davis, G. Davignon, P. Alarcón, R. Dubowy, J. Ducore, M. Dugdale, B. Ewenstein, J. Fahner, T. Gribble, D. Gnarra, R. Gruppo, N. Hakami, M. Hanna, W. Hanna, P. Haut, G. Heggie, A. Homans, J. Hutter, C. Johnson, M. Kajani, M. Karpatkin, Casper Kasper, J. Katz, C. Kessler, N. Key, M. Koerper, B. Konkle, R. Kosinski, J. Lazerson, A. Lightsey, T. Loew, J. Lusher, W. Maclaughlin, M. Manco-Johnson, C. Manno, K. McRedmond, P. Phatak, J. Powell, M. Ragni, C. Rosenfield, J. Sanders, P. Santiago-Borrero, P. Saidi, R. Seeler, S. Seremetis, J. Sexauer, S. Travis, L. Valdez, E. Warner, G. White, D. Barrand, J. Drown, J. Herst, M. Inwood, D. Lillicrap, G. Rivard, S. Rubin, H. Stranczyniski, J. Teitel (2002)
The North American Immune Tolerance Registry: Practices, Outcomes, Outcome PredictorsThrombosis and Haemostasis, 87
-
T. Weimer, W. Wormsbächer, U. Kronthaler, W. Lang, Uwe Liebing, S. Schulte (2008)
Prolonged in-vivo half-life of factor VIIa by fusion to albuminThrombosis and Haemostasis, 99
-
S. Ehrenforth, W. Kreuz, R. Linde, M. Funk, T. Güngör, B. Krackhardt, B. Kornhuber, I. Scharrer (1992)
Incidence of development of factor VIII and factor IX inhibitors in haemophiliacsThe Lancet, 339
-
W. Kreuz (2008)
Immune Tolerance and Choice of Concentrates -
C. Lindley, W. Sawyer, B. Macik, J. Lusher, Justin Harrison, K. Baird-Cox, Kel Birch, Stephen Glazer, H. Roberts (1994)
Pharmacokinetics and pharmacodynamics of recombinant factor VIIaClinical Pharmacology & Therapeutics, 55
-
R. Yatuv, I. Dayan, L. Carmel-Goren, M. Robinson, I. Aviv, M. Goldenberg-Furmanov, M. Baru (2008)
Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomesHaemophilia, 14
-
H. Roberts, D. Monroe, G. White (2004)
The use of recombinant factor VIIa in the treatment of bleeding disorders.Blood, 104 13
-
G. Mariani, B. Kroner (2001)
Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.Haematologica, 86 11
-
Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors
N Engl J Med, 365
-
Prophylaxis versus episodic -
S. Darby, D. Keeling, R. Spooner, S. Kan, P. Giangrande, P. Collins, F. Hill, C. Hay (2004)
The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99Journal of Thrombosis and Haemostasis, 2
-
C. Hay, D. DiMichele (2012)
The principal results of the International Immune Tolerance Study: a randomized dose comparison.Blood, 119 6
-
J. Stockman (2013)
Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with InhibitorsYearbook of Pediatrics, 2013
- Publisher
- de Gruyter
- Copyright
- © 2013 Bert Leenders, published by Sciendo
- eISSN
- 2055-3390
- DOI
- 10.17225/jhp.00003
- Publisher site
- See Article on Publisher Site
Abstract
AbstractHaemophilia A is an X-linked congenital bleeding disorder resulting from a deficiency of factor VIII (FVIII). Therapy to prevent or treat bleeding is by replacement of the missing FVIII. However, as a consequence of treatment, patients with HA may develop inhibitory IgG antibodies to FVIII, termed “inhibitors”. When this occurs, treatment becomes more complex and costly and morbidity increases. Inhibitor formation, occurring in up to 36% of patients with severe HA, is currently one of the most significant complications affecting patients with HA [1,2]. In these two case studies, the management of bleeds in patients with inhibitors, and the long-term inhibitor eradication will be discussed.
Journal
The Journal of Haemophilia Practice – de Gruyter
Published: Jan 1, 2013